CAS 81267-65-4: Phenoxodiol

Dehydroequol is a dietary supplement ingredient, which is a metabolite of the soy isoflavone daidzein. It is produced through the biotransformation by certain gut bacteria that convert daidzein into equol compounds, specifically the dehydrogenated form. This compound is noted for its estrogenic activity, acting primarily as a selective estrogen receptor modulator (SERM). Dehydroequol binds to estrogen receptors with a preference for the beta subtype, exerting moderate estrogenic effects. Dehydroequol's mode of action includes mimicking estrogenic activity in the body, potentially influencing various biological processes. This mechanism is especially relevant in areas such as bone health, cardiovascular function, and menopausal symptoms. Moreover, its role in modulating hormonal activity has garnered interest for applications in oncology, metabolic disorders, and neurodegenerative conditions. Scientists are actively researching its potential therapeutic benefits while considering the variability in individual gut microbiota, which affects its endogenous production and bioavailability. Understanding these interactions aids in elucidating dehydroequol’s full potential and optimizing its application in health and disease management.

Phenoxodiol (Idronoxil) activates the mitochondrial caspase system, inhibits X-linked inhibitor of apoptosis(XIAP), disrupts FLICE inhibitory protein(FLIP)